---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-002187"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:25:04.348364+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics Phase 1 CER-1236 trial shows safety, 61-day transfusion-free interval; expands to MDS/MF

## Summary
- First cohort completed DLT period with no CRS, ICANS, or treatment-related AEs reported.
- Second patient (MDS/AML) had 61-day platelet transfusion-free interval after CER-1236 treatment.
- FDA amendment filed to include advanced MDS and myelofibrosis as additional cohorts.
- Company to host analyst call on Jan 7, 2026 at 5:00 PM ET to discuss progress and strategy.

## SEC filing metadata
- accession: 0001213900-26-002187
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390026002187/0001213900-26-002187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390026002187/ea0272086-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-002187
- JSON: https://secwatch.observer/filing/0001213900-26-002187.json
- Plain text: https://secwatch.observer/filing/0001213900-26-002187.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.